Literature DB >> 23943785

Acacetin inhibits in vitro and in vivo angiogenesis and downregulates Stat signaling and VEGF expression.

Tariq A Bhat1, Dhanya Nambiar, Dhanir Tailor, Arttatrana Pal, Rajesh Agarwal, Rana P Singh.   

Abstract

Angiogenesis is an effective target in cancer control. The antiangiogenic efficacy and associated mechanisms of acacetin, a plant flavone, are poorly known. In the present study, acacetin inhibited growth and survival (up to 92%; P < 0.001), and capillary-like tube formation on Matrigel (up to 98%; P < 0.001) by human umbilical vein endothelial cells (HUVEC) in regular condition, as well as VEGF-induced and tumor cells conditioned medium-stimulated growth conditions. It caused retraction and disintegration of preformed capillary networks (up to 91%; P < 0.001). HUVEC migration and invasion were suppressed by 68% to 100% (P < 0.001). Acacetin inhibited Stat-1 (Tyr701) and Stat-3 (Tyr705) phosphorylation, and downregulated proangiogenic factors including VEGF, endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), matrix metalloproteinase-2 (MMP-2), and basic fibroblast growth factor (bFGF) in HUVEC. It also suppressed nuclear localization of pStat-3 (Tyr705). Acacetin strongly inhibited capillary sprouting and networking from rat aortic rings and fertilized chicken egg chorioallantoic membrane (CAM; ∼71%; P < 0.001). Furthermore, it suppressed angiogenesis in Matrigel plugs implanted in Swiss albino mice. Acacetin also inhibited tyrosine phosphorylation of Stat-1 and -3, and expression of VEGF in cancer cells. Overall, acacetin inhibits Stat signaling and suppresses angiogenesis in vitro, ex vivo, and in vivo, and therefore, it could be a potential agent to inhibit tumor angiogenesis and growth.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23943785      PMCID: PMC3808880          DOI: 10.1158/1940-6207.CAPR-13-0209

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  46 in total

Review 1.  Mechanisms of angiogenesis and arteriogenesis.

Authors:  P Carmeliet
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

Review 2.  Regulation of angiogenesis via vascular endothelial growth factor receptors.

Authors:  T Veikkola; M Karkkainen; L Claesson-Welsh; K Alitalo
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

Review 3.  The STATs of cancer--new molecular targets come of age.

Authors:  Hua Yu; Richard Jove
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

4.  Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.

Authors:  Tariq A Bhat; Dhanya Nambiar; Arttatrana Pal; Rajesh Agarwal; Rana P Singh
Journal:  Carcinogenesis       Date:  2011-12-01       Impact factor: 4.944

5.  Independent prognostic importance of microvessel density in clinically localized prostate cancer.

Authors:  O J Halvorsen; S Haukaas; P A Høisaeter; L A Akslen
Journal:  Anticancer Res       Date:  2000 Sep-Oct       Impact factor: 2.480

Review 6.  Angiogenesis in cancer and other diseases.

Authors:  P Carmeliet; R K Jain
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 7.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

Authors:  Ralf Buettner; Linda B Mora; Richard Jove
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

Review 8.  Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents.

Authors:  Francesca Tosetti; Nicolette Ferrari; Silvio De Flora; Adriana Albini
Journal:  FASEB J       Date:  2002-01       Impact factor: 5.191

9.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.

Authors:  Guilian Niu; Kenneth L Wright; Mei Huang; Lanxi Song; Eric Haura; James Turkson; Shumin Zhang; Tianhong Wang; Dominic Sinibaldi; Domenico Coppola; Richard Heller; Lee M Ellis; James Karras; Jacqueline Bromberg; Drew Pardoll; Richard Jove; Hua Yu
Journal:  Oncogene       Date:  2002-03-27       Impact factor: 9.867

Review 10.  Specialization of tumour vasculature.

Authors:  Erkki Ruoslahti
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

View more
  22 in total

1.  Procyanidin B2 3,3″-di-O-gallate inhibits endothelial cells growth and motility by targeting VEGFR2 and integrin signaling pathways.

Authors:  Rahul Kumar; Gagan Deep; Michael F Wempe; Rajesh Agarwal; Chapla Agarwal
Journal:  Curr Cancer Drug Targets       Date:  2015       Impact factor: 3.428

2.  Induction of growth cessation by acacetin via β-catenin pathway and apoptosis by apoptosis inducing factor activation in colorectal carcinoma cells.

Authors:  Nupoor Prasad; Jiten R Sharma; Umesh C S Yadav
Journal:  Mol Biol Rep       Date:  2019-11-16       Impact factor: 2.316

Review 3.  The Genus Alternanthera: Phytochemical and Ethnopharmacological Perspectives.

Authors:  Rajeev K Singla; Vivek Dhir; Reecha Madaan; Deepak Kumar; Simranjit Singh Bola; Monika Bansal; Suresh Kumar; Ankit Kumar Dubey; Shailja Singla; Bairong Shen
Journal:  Front Pharmacol       Date:  2022-04-11       Impact factor: 5.988

4.  Triple Recycling Processes Impact Systemic and Local Bioavailability of Orally Administered Flavonoids.

Authors:  Peimin Dai; Lijun Zhu; Feifei Luo; Linlin Lu; Qiang Li; Liping Wang; Ying Wang; Xinchun Wang; Ming Hu; Zhongqiu Liu
Journal:  AAPS J       Date:  2015-03-12       Impact factor: 4.009

5.  Synergistic antitumor activity of aspirin and erlotinib: Inhibition of p38 enhanced aspirin plus erlotinib-induced suppression of metastasis and promoted cancer cell apoptosis.

Authors:  Xiu Hu; Lin-Wen Wu; Xu Weng; Neng-Ming Lin; Chong Zhang
Journal:  Oncol Lett       Date:  2018-06-12       Impact factor: 2.967

6.  Endothelial nitric oxide synthase dimerization is regulated by heat shock protein 90 rather than by phosphorylation.

Authors:  Weiguo Chen; Hongbing Xiao; Alicia N Rizzo; Wei Zhang; Yifeng Mai; Meng Ye
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

7.  Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-α pathway.

Authors:  Hsiang-Ping Lee; Chih-Yang Lin; Jhao-Sheng Shih; Yi-Chin Fong; Shih-Wei Wang; Te-Mao Li; Chih-Hsin Tang
Journal:  Oncotarget       Date:  2015-11-03

8.  Tanshinone IIA inhibits angiogenesis in human endothelial progenitor cells in vitro and in vivo.

Authors:  Hsiang-Ping Lee; Yueh-Ching Liu; Po-Chun Chen; Huai-Ching Tai; Te-Mao Li; Yi-Chin Fong; Chih-Shiang Chang; Min-Huan Wu; Li-Pin Chiu; Chia-Jung Wang; Yi-Hsuan Chen; Yih-Jer Wu; Chih-Hsin Tang; Shih-Wei Wang
Journal:  Oncotarget       Date:  2017-11-24

9.  WISP-1 promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-300 in human oral squamous cell carcinoma cells.

Authors:  Ching-Chia Lin; Po-Chun Chen; Ming-Yu Lein; Ching-Wen Tsao; Chiu-Chen Huang; Shih-Wei Wang; Chih-Hsin Tang; Kwong-Chung Tung
Journal:  Oncotarget       Date:  2016-03-01

10.  Basic fibroblast growth factor promotes VEGF-C-dependent lymphangiogenesis via inhibition of miR-381 in human chondrosarcoma cells.

Authors:  Huey-En Tzeng; An-Chen Chang; Chun-Hao Tsai; Shih-Wei Wang; Chih-Hsin Tang
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.